CU23812A1 - CHIMERIC SYNTHETIC PEPTIDES OF HIV-1 ENVELOPE PROTEIN (GP120) - Google Patents
CHIMERIC SYNTHETIC PEPTIDES OF HIV-1 ENVELOPE PROTEIN (GP120)Info
- Publication number
- CU23812A1 CU23812A1 CU20100072A CU20100072A CU23812A1 CU 23812 A1 CU23812 A1 CU 23812A1 CU 20100072 A CU20100072 A CU 20100072A CU 20100072 A CU20100072 A CU 20100072A CU 23812 A1 CU23812 A1 CU 23812A1
- Authority
- CU
- Cuba
- Prior art keywords
- hiv
- peptides
- synthetic peptides
- envelope protein
- protein
- Prior art date
Links
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 101710091045 Envelope protein Proteins 0.000 title 1
- 101710188315 Protein X Proteins 0.000 title 1
- 102100021696 Syncytin-1 Human genes 0.000 title 1
- 108091006116 chimeric peptides Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 150000002333 glycines Chemical class 0.000 abstract 1
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Péptidos quiméricos obtenidos mediante síntesis química en fase sólida, que contienen dos secuencias inmunodominantes, correspondientes a la región C-terminal y al lazo V3, de la proteína gp120 de la envoltura del VIH-1, separadas por dos glicinas como brazo espaciador. La antigenicidad de los péptidos quiméricos fue superior al de los péptidos monoméricos por separado. Estos péptidos pueden ser utilizados como antígenos en ensayos para la detección de anticuerpos específicos a la proteína gp120 del VIH-1, en la certificación de la sangre de donantes y en la vigilancia epidemiológica.Chimeric peptides obtained by chemical solid-phase synthesis, containing two immunodominant sequences, corresponding to the C-terminal region and the V3 loop, of the gp120 protein of the HIV-1 envelope, separated by two glycines as a spacer arm. The antigenicity of the chimeric peptides was superior to that of the monomeric peptides separately. These peptides can be used as antigens in assays for the detection of antibodies specific to the gp120 protein of HIV-1, in the certification of donor blood and in epidemiological surveillance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20100072A CU23812A1 (en) | 2010-04-23 | 2010-04-23 | CHIMERIC SYNTHETIC PEPTIDES OF HIV-1 ENVELOPE PROTEIN (GP120) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20100072A CU23812A1 (en) | 2010-04-23 | 2010-04-23 | CHIMERIC SYNTHETIC PEPTIDES OF HIV-1 ENVELOPE PROTEIN (GP120) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23812A1 true CU23812A1 (en) | 2012-04-15 |
Family
ID=46021917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20100072A CU23812A1 (en) | 2010-04-23 | 2010-04-23 | CHIMERIC SYNTHETIC PEPTIDES OF HIV-1 ENVELOPE PROTEIN (GP120) |
Country Status (1)
| Country | Link |
|---|---|
| CU (1) | CU23812A1 (en) |
-
2010
- 2010-04-23 CU CU20100072A patent/CU23812A1/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120976T1 (en) | TWO SPECIFIC IGG ANTIBODIES AS TYP CELL ACTIVATING FACTORS | |
| EA201400108A1 (en) | OPTIONS OF POLYPEPTIDES AND THEIR APPLICATIONS | |
| MX354660B (en) | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins. | |
| MX2014005108A (en) | POLYPEPTIDE CONSTRUCTS AND THEIR USES. | |
| CL2017002199A1 (en) | Retroviral to Lentiviral Vectors | |
| EA201290722A1 (en) | RECOMBINANT PROTEIN EXENDIN-4 AND ITS ANALOGUE, METHOD OF THEIR PREPARATION AND USE | |
| NZ607969A (en) | Cd33 binding agents | |
| CY1121323T1 (en) | ANTIBODIES NEUTRALIZING THE HUMAN IMMUNE DISEASE VIRUS (HIV) | |
| MX361076B (en) | Disulfide-linked multivalent mhc class i comprising multi-function proteins. | |
| MX2016015383A (en) | Anti-human papillomavirus 16 e7 t cell receptors. | |
| AR095374A1 (en) | UNION MOLECULES FOR BCMA AND CD3 | |
| MX365658B (en) | Compositions comprising aav expressing dual antibody constructs and uses thereof. | |
| WO2012030904A3 (en) | Human immunodeficiency virus (hiv)-neutralizing antibodies | |
| UA115436C2 (en) | Anticancer fusion protein | |
| MX2012003058A (en) | VACCINES DIRECTED TO LANGERHANS CELLS. | |
| BR112016014920A2 (en) | new human anti-bdca-2 antibody | |
| WO2009099777A3 (en) | Chimeric hiv fusion proteins as vaccines | |
| UY37975A (en) | NEW ANTIGENS OF PROTEINS OF THE HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE (HIV) EXPRESSED IN CELLS OF MAMMALS | |
| Molinos-Albert et al. | Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals | |
| EA201400216A1 (en) | CANNING OF BIOLOGICAL PRODUCTS, IN PARTICULAR VACCINES, WITH THE APPLICATION OF VACUUM | |
| TR201905447T4 (en) | New mhc independent tumor associated antigens. | |
| MX2022008298A (en) | ANTIBODY TO BIASING SEX PROPORTIONS AND METHODS OF USE THE SAME. | |
| WO2011082422A3 (en) | Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications | |
| MX385451B (en) | SELF-ASSEMBLING SYNTHETIC PROTEINS. | |
| AR094987A1 (en) | IMPROVED PROCESS FOR HIGH PERFORMANCE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |